在心力衰竭中使用修改的亚洲萨尔科佩尼亚工作组2019年标准评估了萨尔科佩尼亚的预后影响
Taisuke Nakade1, Daichi Maeda1, Yuya Matsue1
1Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
The Canadian journal of cardiology
|August 22, 2024
概括
使用6分钟步行测试 (6MWT) 修改的亚洲肉症工作组 (AWGS) 2019标准改善了心力衰竭患者的风险分层. 这种方法比原来的AWGS 2019模型更好地预测2年死亡率.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 物理医学和康复 康复
背景情况:
- 麻症是关键的治疗目标,但它在使用2019年AWGS标准的心力衰竭患者中的风险分层有效性尚未得到证实.
- 6分钟步行测试 (6MWT) 是评估身体表现和改善这一群体风险分层的潜在工具.
研究的目的:
- 评估2019年AWGS标准对心力衰竭患者的萨尔科佩尼亚风险分层的有效性.
- 为了确定是否将6MWT纳入肉症评估,可以改善2年死亡率的风险预测.
主要方法:
- 包括832名住院的心力衰竭患者,这些患者在出院时能够走路.
- 使用原始的AWGS 2019标准和修改后的模型,用6MWT (<300m表示性能低) 取代体力表现,诊断出肉症.
- 主要结局是2年死亡率.
主要成果:
- 修改后的模型发现了比原始的AWGS 2019模型更多的肉类和严重肉类病例.
- 在修改后的模型中,sarcopenia和严重的sarcopenia都与2年死亡率有显著的关联,而在原始模型中,只有严重的sarcopenia是显著的.
- 修改后的模型显示,与原来的AWGS 2019模型相比,净重新分类 (NRI) 显著改善 (NRI,0.396;P < 0.001).
结论:
- 使用修改后的AWGS 2019模型与6MWT进行的萨尔科佩尼亚评估,增强了门诊心力衰竭患者的风险分层.
- 目前的肉症标准需要重新考虑,以改善风险分层,并确保对心力衰竭患者及时治疗.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405


